Akt1-IN-8 (Compound JL18) is a potent and oral bioavailable (41%) inhibitor of AKT1 kinase , with an IC 50 of 8.8 nM. Akt1-IN-8 exhibits significant antiproliferative effects against PC-3 prostate cancer cells, with an IC 50 of 3.0 μM. Akt1-IN-8 can reduce phosphorylated GSK3β levels.
Products | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Akt
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.